Rare diseases: specific challenges for sustainable accessibility of treatments for patients
Lucas Cortial , Pierre-Olivier Boyer , Sylvain Forget , Ronan Le Joubioux , Olivier Blin , Franck Mouthon
Rare Disease and Orphan Drugs Journal ›› 2022, Vol. 1 ›› Issue (3) : 12
Rare diseases: specific challenges for sustainable accessibility of treatments for patients
In late 2021, the health technology assessment of the French National Authority for Health was seized by the French Ministry of Solidarity and Health to address a specific challenge, the identification of solutions contributing to the development of the methodological expertise in new types of clinical studies for rare diseases. Experts from the rare diseases environment were gathered by OrphanDev, the French network of expertise dedicated to rare diseases. They allowed to identify some of the current issues in France concerning rare diseases, and then present different solutions, in particular related to the evaluation process of orphan drugs and the collection of data on rare diseases.
Rare diseases / evaluation process / France / orphan drug / real-life data
| [1] |
|
| [2] |
HAS. Transparency committee doctrine. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2019-07/doctrine_de_la_commission_de_la_transparence_-_version_anglaise.pdf [Last accessed on 6 Jun 2022] |
| [3] |
HAS. Real-world studies for the assessment of medicinal products and medical devices. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2021-10/real-world_studies_for_the_assessment_of_medicinal_products_and_medical_devices.pdf [Last accessed on 6 Jun 2022] |
| [4] |
PFIZER. Plaidoyer pour une reconnaissance de la perspective patient dans l’évaluation des prodiits de sante. Available from: https://www.pfizer.fr/sites/default/files/inline-files/Plaidoyer%20pour%20la%20reconnaissance%20de%20la%20perspective%20patient%20dans%20l%27%C3%A9valuationVF.pdf [Last accessed on 6 Jun 2022] |
| [5] |
|
| [6] |
|
/
| 〈 |
|
〉 |
PDF
